Ⅰ-Ⅱ期非小细胞肺癌中央型肿瘤部分接受风险适应性立体定向体部放疗的亚组生存分析
研究纳入765例接受立体定向体部放疗的早期非小细胞肺癌患者,中位剂量3×18 Gy,中央型肿瘤中第一厘米组55%、第二厘米组27%接受风险适应性(低强度)方案(多为8次)。结果显示第一厘米组非癌死亡风险显著高于其他组(HR 3.175,P<.001),第二厘米组与周围型组无差异(P=.53); proximal支气管树高剂量与 非癌死亡相关(D1% HR 1.006 Gy⁻¹,P=.003)。
要点
- 第一厘米组非癌死亡风险为其他组的3.175倍(P<.001)。
- 第二厘米组非癌死亡与周围型组无显著差异(P=.53)。
- proximal支气管树D1%每增加1 Gy,非癌死亡风险HR 1.006(P=.003)。
核心结论
- GTV位于 proximal支气管树周围第一厘米的患者较其他患者更常死于非癌原因。
- GTV位于第二厘米的患者部分接受风险适应性方案,其非癌死亡与周围型肿瘤患者相当。
研究设计与样本
- 研究纳入765例接受立体定向体部放疗的早期非小细胞肺癌患者,中位剂量3×18 Gy。
- 中央型肿瘤中,第一厘米组55%、第二厘米组27%的患者接受风险适应性(低强度)方案(多为8次)。
- 将平均解剖轮廓的 proximal支气管树和危及器官变形至每位患者,以获得GTV至 proximal支气管树的距离和危及器官剂量。
- 采用对数秩检验、单因素方差分析和Cox回归评估第一厘米组、第二厘米组和周围型组间的差异及与非癌死亡的关联。
主要发现
- 中位总生存期为42.7个月,中位非癌死亡时间为57.3个月,中位随访时间为34.8个月。
- 第一厘米组(31例)非癌死亡与其他组显著不同,风险比3.175(P<.001)。
- 第二厘米组(71例)非癌死亡与周围型组无差异(P=.53)。
- 第一厘米组和第二厘米组所有危及器官的剂量均高于周围型组。
- proximal支气管树高剂量与非癌死亡相关(D1%;风险比1.006 Gy⁻¹;P=.003)。
关键数值与推荐
- 第一厘米组非癌死亡风险比3.175(P<.001)。
- 第二厘米组与周围型组非癌死亡比较P=.53。
- proximal支气管树D1%风险比1.006 Gy⁻¹(P=.003)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Stereotactic body radiation therapy has been associated with increased toxicity when delivered to patients with early-stage non-small cell lung cancer with a tumor within 2 cm of the proximal bronchial tree (PBT). We investigated noncancer deaths for these patients as related to gross tumor volume (GTV) proximity to the PBT, compared with peripheral tumors. METHODS AND MATERIALS: We included 765 patients with early-stage non-small cell lung cancer who were treated with stereotactic body radiation therapy to a median of 3 × 18 Gy. Central tumors were treated with a risk-adapted (less-intense) schedule (mostly 8 fractions) in 55% of the patients in the first-centimeter group and 27% of the patients in the second-centimeter group. An average anatomy with contouring of PBT and organs at risk (OARs) was deformed onto each patient to obtain the distance of the GTV to the PBT and doses to OARs. Log-rank, 1-way analysis of variance, and Cox regressions were performed to assess differences in the first-centimeter, second centimeter, and peripheral groups and associations with noncancer deaths. RESULTS: The median overall survival was 42.7 months, the median noncancer death occurred in 57.3 months, and the median follow-up was 34.8 months. Noncancer death in the first-centimeter group (31 patients) was significantly different from noncancer death in the other groups, with a hazard ratio of 3.175 (P < .001). Noncancer death in the second-centimeter group (71 patients) was not different from noncancer death in the peripheral group (P = .53). Doses to OARs were higher in the first- and second-centimeter groups than in the peripheral group for all OARs. High dose to the PBT was associated with noncancer death (D1%; hazard ratio, 1.006 Gy-1; P = .003). CONCLUSIONS: Patients with a GTV in the first centimeter surrounding the PBT died more often from causes other than cancer compared with other patients. Noncancer death in patients with a GTV in the second centimeter, who partly received a risk-adapted schedule, was comparable to that in patients with a peripheral tumor.
引用
- Stam B, Kwint M, Guckenberger M, et al. Subgroup Survival Analysis in Stage I-II NSCLC Patients With a Central Tumor Partly Treated With Risk-Adapted SBRT. Int J Radiat Oncol Biol Phys. 2018. PMID: 30176275. doi:10.1016/j.ijrobp.2018.08.040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。